Italia markets close in 2 hours 55 minutes
FTSE MIB
33.521,83 -46,64 (-0,14%) Dow Jones
41.393,78 +296,98 (+0,72%) Nasdaq
17.683,98 +114,28 (+0,65%) Nikkei 225
36.581,76 -251,54 (-0,68%) Petrolio
69,23 +0,58 (+0,84%) Bitcoin EUR
52.658,54 -1.284,10 (-2,38%)
PFE Mar 2025 36.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:27AM EDT. Mercato aperto.
| Chiusura precedente | 5,70 |
| Aperto | N/D |
| Denaro | 6,90 |
| Domanda | 8,00 |
| Prezzo d'esercizio | 36,00 |
| Scadenza | 2025-03-21 |
| Min-Max giorno | 5,70 - 5,70 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 2 |
GlobeNewswireArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g
© 2024 Yahoo. Tutti i diritti riservati.